Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
ConditionContraceptive Usage
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorOregon Health and Science University
About this trial
The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
Eligibility criteria
Qualifiers
Generally healthy women
Aged 18-40
regular menses (every 21-35 days) experiencing ovulatory cycles proven by a single progesterone level of 3 ng/mL or greater during the luteal phase of the screening cycle.
Disqualifiers
Pregnant, seeking pregnancy, or breastfeeding
Known allergy to study medication
Recent use of hormonal contraception
Irregular periods (<21 days or >35 day cycles)
Trial design
Treatments tested in this trial
- Ulipristal acetate
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Oregon Health and Science University
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Source ClinicalTrials.gov